CDR-Life has reached a development milestone with its antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA).
Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021.
GA is a progressive, irreversible retinal disease and one of the leading causes of blindness in people over 65 years of age. It occurs in people living with age-related macular degeneration (AMD) and affects approximately eight million people globally.
Christian Leisner, Chief Executive Officer at CDR-Life, said: “Our partnership with Boehringer Ingelheim has proven successful and will hopefully bring life changing new treatments for people living with this devastating disease.”
In addition to partnering with Boehringer Ingelheim, CDR-Life is building its own pipeline of novel antibody fragment-based T cell engagers against solid tumours, targeting the major histocompatibility complex (MHC). The company’s first of several therapeutic candidates in development, CDR404, targets MAGE-A4 and is anticipated to enter the clinic in 2024.
Edited by: Diana Spencer, Senior Digital Content Editor, Drug Discovery World
